Matinas BioPharma (NYSEAMERICAN:MTNB) Shares Gap Up to $1.04

Matinas BioPharma Holdings Inc (NYSEAMERICAN:MTNB)’s stock price gapped up prior to trading on Monday . The stock had previously closed at $0.98, but opened at $1.04. Matinas BioPharma shares last traded at $1.24, with a volume of 333,639 shares.

Several equities analysts have recently weighed in on the stock. Maxim Group reiterated a “buy” rating and issued a $3.00 price objective on shares of Matinas BioPharma in a research note on Thursday, September 26th. HC Wainwright reiterated a “buy” rating and issued a $4.00 price objective on shares of Matinas BioPharma in a research note on Wednesday, August 14th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $3.60.

The company’s 50 day moving average price is $0.68 and its two-hundred day moving average price is $0.89.

Matinas BioPharma (NYSEAMERICAN:MTNB) last issued its quarterly earnings data on Wednesday, November 13th. The company reported ($0.03) earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.03).

A number of institutional investors have recently added to or reduced their stakes in the stock. BlackRock Inc. lifted its stake in shares of Matinas BioPharma by 5.0% in the second quarter. BlackRock Inc. now owns 633,985 shares of the company’s stock worth $543,000 after acquiring an additional 30,402 shares in the last quarter. Northern Trust Corp lifted its stake in shares of Matinas BioPharma by 30.1% in the second quarter. Northern Trust Corp now owns 236,818 shares of the company’s stock worth $203,000 after acquiring an additional 54,852 shares in the last quarter. Wells Fargo & Company MN lifted its stake in shares of Matinas BioPharma by 297.2% in the second quarter. Wells Fargo & Company MN now owns 103,274 shares of the company’s stock worth $88,000 after acquiring an additional 77,274 shares in the last quarter. Bank of New York Mellon Corp lifted its stake in shares of Matinas BioPharma by 175.7% in the second quarter. Bank of New York Mellon Corp now owns 154,558 shares of the company’s stock worth $132,000 after acquiring an additional 98,501 shares in the last quarter. Finally, Staley Capital Advisers Inc. acquired a new position in shares of Matinas BioPharma in the second quarter worth about $171,000.

Matinas BioPharma Company Profile (NYSEAMERICAN:MTNB)

Matinas BioPharma Holdings, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. The company enables the delivery of life-changing medicines using its lipid nano-crystal (LNC) platform technology. Its LNC delivery technology platform utilizes lipid nano-crystals which can encapsulate small molecules, oligonucleotides, vaccines, peptides, proteins and other medicines potentially making them safer, more tolerable, less toxic, and orally bioavailable.

Featured Article: Why is total return important?

Receive News & Ratings for Matinas BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Matinas BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.